News
CS-BLAP platform launch
Full public release of the CS-BLAP long-acting classification and IVIVC platform.
SAAM v2.5
Improved UI
AOMM v1.3
AOMM in beta version.
ATTD Barcelona — AOMM presented
Simone Perazzolo presented Automated Oral Minimal Modeling (AOMM) for insulin sensitivity to clinicians and scientists at ATTD Barcelona.
CS-BLAP — Journal of Pharmaceutical Sciences
Perazzolo, Shen & Ho propose a classification system to guide the design, development, regulatory approval, and scaling of long-acting small- and macro-molecule parenteral products.
→ publicationAnnual Review of Pharmacology and Toxicology — long-acting therapeutics
Olagunju, Perazzolo et al. review the promises and prospects of long-acting therapeutics for the treatment and prevention of infectious diseases.
→ publicationUKPK Workshop — University of Warwick
Simone presented on scaling PK from animals to humans, with a focus on long-acting injectable modeling strategies.
→ event page1st International Workshop on Long-Acting Anti-Infectives (LAAI) — New Orleans
Nanomath presented at the inaugural LAAI workshop covering long-acting and extended-release therapies for HIV, TB, and malaria.
→ watchPAGE 2025 — Greece
Nanomath participated in PAGE 2025, showcasing SAAM II capabilities and networking with the population PK/PD community.
→ meeting pageCROI 2025 — LEAP Workshop
Simone presented updates on the Drug-Combination Platform Phase 1 clinical trial and the long-acting small molecule transformation platform.
→ CROIAOMM published — Journal of Diabetes Science and Technology
Peer-reviewed article on Automated Oral Minimal Model Analysis and its applications in large-scale clinical research.
→ publicationLong-acting injectable lopinavir — Journal of Infectious Diseases
Long-acting injectable lopinavir eliminates reliance on ritonavir, advancing LA HIV therapy options.
→ publicationSAAM II — automated oral minimal model integrated
SAAM II updated to include the first automated oral minimal model analysis, enabling deployment in large-scale diabetes trials.
▸2024
International Workshop on Clinical Pharmacology — Liverpool
Simone gave an invited panel talk on modeling and simulation's role in advancing long-acting injectable development.
→ workshop pageAIDS 2024 — poster on pediatric LA dosing
Poster presentation on physiologically-based PK modeling for pediatric dosing of TLC-ART-101, a long-acting triple-drug injectable.
→ programmePAGE 2024 — Rome
Nanomath participated in Population Approach Group Europe 2024, presenting SAAM II capabilities.
→ meeting pageDrug-drug interaction study for LA injectable nanoparticles
Research on drug interactions and multiple dosing in long-acting nanoparticle formulations, Journal of Pharmaceutical Sciences.
→ publicationEURADOS-ICRP — SAAM II selected as official kinetic software
SAAM II designated as the official software for dose determination after internal contamination in the EURADOS-ICRP training program.
→ course infoSAAM II featured in Pfizer pipeline review — Cancer Cell
Review highlights SAAM II integration for PK-PD modeling by Pfizer scientists in a CDK4 selective inhibition study.
→ publication
▸2023
PAGE 2023 — proceedings highlight
Featured coverage from the 31st PAGE Meeting proceedings, second day.
PAGE 2023 — A Coruña, Spain
SAAM II: Selected Software Use Cases in Modern PK-PD Data Analysis.
→ abstractPBPK & nanoformulation — Seattle
Simone presented on physiologically-based pharmacokinetic modeling and nanoformulation at the Long-Acting HIV conference.
→ conference
▸2022
AAPS PharmSci 360 — Boston
Emerging role of systems pharmacology, long-acting therapeutics, and targeted drug-combination technology.
→ coverageTwo-year anniversary — TG Leonardo (Italy)
President's interview on pandemic-era research, achieving over 2 million views in Italy.
→ watchPBPK of 3 HIV drugs in combination — Part 2
Drug-combination nanoparticle modeling, Journal of Pharmaceutical Sciences.
→ publicationPBPK of 3 HIV drugs in combination — Part 1
Free-drug mixture modeling and the role of the lymphatic system, Journal of Pharmaceutical Sciences.
→ publication
▸2021
FDA approves valbenazine (Ingrezza) new dose
Approval facilitated through Model-Informed Drug Development (MIDD), integrating exposure-based and statistical models.
→ FDA announcement
▸2020
Long-acting HIV injectables — PK modeling talk
Simone Perazzolo presented on pharmacokinetic modeling for long-acting HIV injectable development.
RAI Italy Tg3 — media coverage
Media appearance discussing Nanomath's pharmaceutical research work.